Home › Research › Getting a diagnosis
Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial
Fowler NR, Perkins AJ, Gao S, Bakas T, Head KJ, Higbie A, Baucco C, Callahan CM, Williams-Farrelly MM, Boustani MA. JAMA Internal Medicine, 2026-06-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Results A total of 1808 dyads completed baseline assessments. Overall, 62 patients (5.1%) screened positive for cognitive impairment. There were no significant differences between the combined screening groups and no-screening group in SF-36 physical (24-month predicted difference, -0.21; 95% CI, -1.26-0.85) or mental (24-month predicted difference, 0.58; 95% CI, -0.18-1.33) component scores. Discussion This randomized clinical trial found that ADRD screening in PC was not associated with improvement in family member health-related quality of life, caregiver preparedness, or caregiving self-efficacy. Screening was also not associated with increased family member depression or anxiety. Low rates of positive screening and high rates of refusal for follow-up diagnostic assessment may help explain these findings.
What this study adds
Evidence grade: Null result
The record lists 1,808 participants. This trial found that dementia screening in primary care did not improve family members' health-related quality of life, caregiver preparedness, or caregiving self-efficacy. Reported effect size: 24-month SF-36 mental component difference 0.58 (95% CI -0.18 to 1.33), not significant.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fowler, N. R., Perkins, A. J., Gao, S., Bakas, T., Head, K. J., Higbie, A., et al. (2026). Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.0844
Vancouver
Fowler NR, Perkins AJ, Gao S, Bakas T, Head KJ, Higbie A, et al. Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial. JAMA Internal Medicine. 2026. doi:10.1001/jamainternmed.2026.0844. PMID: 42008257.
BibTeX
@article{fowler2026-42008257,
author = {Fowler, N. R. and Perkins, A. J. and Gao, S. and Bakas, T. and Head, K. J. and Higbie, A. and Baucco, C. and Callahan, C. M. and Williams-Farrelly, M. M. and Boustani, M. A.},
title = {{Benefits and Harms of Dementia Screening for Family Members of Older Adults: A Randomized Clinical Trial}},
journal = {JAMA Internal Medicine},
year = {2026},
doi = {10.1001/jamainternmed.2026.0844},
pmid = {42008257},
url = {https://doi.org/10.1001/jamainternmed.2026.0844}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 10 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results A total of 1808 dyads completed baseline assessments.
- Overall, 62 patients (5.1%) screened positive for cognitive impairment.
- There were no significant differences between the combined screening groups and no-screening group in SF-36 physical (24-month predicted difference, -0.21; 95% CI, -1.26-0.85) or mental (24-month predicted difference, 0.58; 95% CI, -0.18-1.33) component scores.
- Discussion This randomized clinical trial found that ADRD screening in PC was not associated with improvement in family member health-related quality of life, caregiver preparedness, or caregiving self-efficacy.
- Screening was also not associated with increased family member depression or anxiety.
Why it matters
This trial found that dementia screening in primary care did not improve family members' health-related quality of life, caregiver preparedness, or caregiving self-efficacy. Screening also did not increase family member depression or anxiety.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designRCT
- Participants1,808
- Effect size24-month SF-36 mental component difference 0.58 (95% CI -0.18 to 1.33), not significant
- Evidence strengthNull-result
Limitations
Low positive-screen rate and high refusal of follow-up limit power to detect effects of an actual diagnosis; screening tools were brief (Mini-Cog, MIS-T); single US health system region.
How this study scored 60/100
Published in a leading specialty journal, and it is a randomized controlled trial. We have no data on free to read, so that was left out: it earned 59 of the 98 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA Internal Medicine) |
| Journal's citation record | 3 / 4 | JAMA Internal Medicine: journal h-index 258 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 3 / 5 | Rated “null-result” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,808 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Malaz A. Boustani: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Indiana University: institution h-index 926 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42008257) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 59 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 98 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamainternmed.2026.0844
- PubMed: 42008257
- Original source →
- Free full text: pmc.ncbi.nlm.nih.gov →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Related studies in Getting a diagnosis from nearby years
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.